Recent Finacing
Recent Raise
Oxford Vacmedix develops peptide-based cancer vaccines using an overlapping short-peptide platform and bacterial synthesis to advance HPV and survivin-targeted candidates toward phase 1, with Asia R&D and Chinese licensing.
